TIM‐3 and CEACAM1 do not interact in cis and in trans

TIM‐3 has been considered as a target in cancer immunotherapy. In T cells, inhibitory as well as activating functions have been ascribed to this molecule. Its role may therefore depend on the state of T cells and on the presence of interaction partners capable to perform functional pairing. Carcinoe...

Descripción completa

Detalles Bibliográficos
Autores principales: De Sousa Linhares, Annika, Kellner, Florian, Jutz, Sabrina, Zlabinger, Gerhard J., Gabius, Hans‐Joachim, Huppa, Johannes B., Leitner, Judith, Steinberger, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Adaptive immunity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496933/
https://www.ncbi.nlm.nih.gov/pubmed/32222966
http://dx.doi.org/10.1002/eji.201948400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496933/
https://www.ncbi.nlm.nih.gov/pubmed/32222966
http://dx.doi.org/10.1002/eji.201948400

Ejemplares similares